Early clinical experience and impact of f-fdg pet

Nuclear Medicine Communications

Volumn 26, Issue 11, 2005, Pages 989-994

  Gutte, Henrik ^a   Højgaard, Liselotte ^b   Kjær, Andreas ^b  

^a Nuclear Medicine and PET ^*  (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer; Clinical impact; FDG PET; Nuclear medicine; Survey

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CHEMOTHERAPY; DIAGNOSTIC PROCEDURE; DIGESTIVE SYSTEM CANCER; FEMALE; HEALTH SURVEY; HEMATOLOGY; HUMAN; IMAGING; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEOPLASM; NERVOUS SYSTEM TUMOR; NEUROLOGY; ONCOLOGY; PHYSICIAN; PLASTIC SURGERY; POSITRON EMISSION TOMOGRAPHY; QUESTIONNAIRE; SATISFACTION; TIME SERIES ANALYSIS; TREATMENT PLANNING;

DATA COLLECTION; DENMARK; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REFERRAL AND CONSULTATION;

EID: 27344445329     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000184940.06123.f0     Document Type: Article

References (28)

1. Phelps ME. PET provides molecular imaging of biological processes. Proc Natl Acad Sci USA 2000; 97:9226-9233.
2. Brix G, Noßke D, Glatting G, Minkov V, Reske SN. A survey of PET activity in Germany during 1999. Eur J Nucl Med 2002; 29:1091-1097.
3. 111In-granulocyte scintigraphy. Eur J Nucl Med Mol Imaging 2004; 31:622-626.
4. Fischer BM, Mortensen J, Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncology 2001; 2:659-666.
5. Hauber HP, Bohuslavizki KH, Lund CH, Fritscher-Ravens A, Meyer A, Pforte A. Positron emission tomography in the staging of small-cell lung cancer: a preliminary study. Chest 2001; 119:950-954.
6. Schumacher T, Brink I, Mix M, et al. FDG-PET imaging for the staging and follow-up of small cell lung cancer. Eur J Nucl Med 2001; 28:483-488.
7. 18F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 2002; 43:492-499.
8. Shoder H, Yeung WD. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med 2004; 34:180-197.
9. Klose T, Leidl R, Buchmann I, et al. Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography. Eur J Nucl Med 2000; 27:1457-1464.
10. 18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies. Gut 2003; 52(suppl 4):23-29.
11. Scwimmer J, Essner R, Patel A, Jahan SA, Shepherd JE, Park K, et al. A review of the litterature for wholebody FDG PET in the management of patients with melanoma. Q J Nucl Med 2000; 44:153-167.
12. Eubank WB, Mankoff DA. Current and future uses of positron emission tomography in breast cancer imaging. Semin Nucl Med 2004; 34:224-240.
13. Tucker R, Coel M, Ko J, Morris P, Druger G, McGuigan P. Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: first year's experience in a clinical center. J Clin Oncol 2001; 19:2504-2508.
14. Gopalan D, Griffiths D, Townsend C, Prvulovich E, Bomanji J, Costae DC, Ell PJ. Flurodeoxyglucose positron emission tomography in clinical oncology: the referrer's perspective. Nucl Med Commun 2002; 23:1041-1046.
15. Hillner B, Tunuguntla R, Fratkin M. Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one United States center. J Clin Oncol 2004; 22:4147-4156.
16. 18F) fluoro-D-glucose whole body positron emission tomography for managing patients with melanoma: the referring physicians perspective. Mol Imag Biol 2002; 4:185-190.
17. 18F-fluorodeoxyglucose positron emission tomography in recurrent melanoma. Nucl Med Com 2002; 23:475-481.
18. Gulec SA, Faries MB, Lee CC, Kirgan D, Glass C, Morton DL, Essner R. The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med 2003; 28:961-965.
19. 18F-FDG PET imaging on clinical staging and managing patients with malignant lymphoma. J Nucl Med 2001; 42:1139-1143.
20. Seltzer MA, Yap CS, Silverman DH, Meta J, Schiepers C, Phelps ME, et al. The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med 2002; 43:752-756.
21. Kamel E, Zwahlen D, Wyss M, Stumpe KD, Schultess GK, et al. Whole-body 18-F-FDG improves the management of patients with small cell lung cancer. J Nucl Med 2003; 44:1911-1917.
22. Hicks RJ, Kalff V, MacManus MP, Ware RE, Hogg A, McKenzie AF, et al. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001; 42:1596-604.
23. 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. J Nucl Med 2001; 42:586-590.
24. Arulampalam T, Costa D, Visvikis D, Boulos P, Taylor I, Ell P. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer. Eur J Nucl Med 2001; 28:1758-1765.
25. Heriot AG, Hicks RJ, Drummond EG, Keck J, Mackay J, Chen F, Kalff V. Does positron emission tomography change management in primary rectal cancer? A prospective assessment. Dis Colon Rectum 2004; 47: 451-458.
26. Lonneux M, Reffad AM. Metastases from unknown primary tumor: PET-FDG as initial diagnostic procedure? Clin Pos Imag 2000; 3:137-141.
27. Alberini JL, Belhocine RH, Daenn F, Rigo P. Whole-body positron emission tomography using fluorodeoxyglucose in patients with metastases of unknown primary tumours (CUP syndrome). Nucl Med Commun 2003; 24:1081-1086.
28. 18F-FDG PET on staging and managing patients with breast cancer: the referring physician's perspective. J Nucl Med 2001; 42:1334-1337.